(Q44539030)

English

Improving efficiency and sensitivity: European Research Initiative in CLL (ERIC) update on the international harmonised approach for flow cytometric residual disease monitoring in CLL.

scientific article published on 31 July 2012

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

3 December 2017

Improving efficiency and sensitivity: European Research Initiative in CLL (ERIC) update on the international harmonised approach for flow cytometric residual disease monitoring in CLL. (English)

1 reference

Europe PubMed Central

PubMed publication ID

3 December 2017

1 reference

based on heuristic

inferred from title

Andy C Rawstron

1

1 reference

Europe PubMed Central

PubMed publication ID

3 December 2017

3

1 reference

Europe PubMed Central

PubMed publication ID

3 December 2017

18

1 reference

Europe PubMed Central

PubMed publication ID

3 December 2017

author name string

S Böttcher

2

1 reference

Europe PubMed Central

PubMed publication ID

3 December 2017

N Villamor

4

1 reference

Europe PubMed Central

PubMed publication ID

3 December 2017

C Fazi

5

1 reference

Europe PubMed Central

PubMed publication ID

3 December 2017

H Kartsios

6

1 reference

Europe PubMed Central

PubMed publication ID

3 December 2017

R M de Tute

7

1 reference

Europe PubMed Central

PubMed publication ID

3 December 2017

J Shingles

8

1 reference

Europe PubMed Central

PubMed publication ID

3 December 2017

M Ritgen

9

1 reference

Europe PubMed Central

PubMed publication ID

3 December 2017

C Moreno

10

1 reference

Europe PubMed Central

PubMed publication ID

3 December 2017

K Lin

11

1 reference

Europe PubMed Central

PubMed publication ID

3 December 2017

A R Pettitt

12

1 reference

Europe PubMed Central

PubMed publication ID

3 December 2017

M Kneba

13

1 reference

Europe PubMed Central

PubMed publication ID

3 December 2017

E Montserrat

14

1 reference

Europe PubMed Central

PubMed publication ID

3 December 2017

F Cymbalista

15

1 reference

Europe PubMed Central

PubMed publication ID

3 December 2017

M Hallek

16

1 reference

Europe PubMed Central

PubMed publication ID

3 December 2017

P Hillmen

17

1 reference

Europe PubMed Central

PubMed publication ID

3 December 2017

European Research Initiative in CLL

19

1 reference

Europe PubMed Central

PubMed publication ID

3 December 2017

publication date

31 July 2012

1 reference

Europe PubMed Central

PubMed publication ID

3 December 2017

number of pages

8

1 reference

based on heuristic

inferred from page(s)

1 reference

Europe PubMed Central

PubMed publication ID

3 December 2017

27

1 reference

Europe PubMed Central

PubMed publication ID

3 December 2017

1

1 reference

Europe PubMed Central

PubMed publication ID

3 December 2017

142-149

1 reference

Europe PubMed Central

PubMed publication ID

3 December 2017

https://scigraph.springernature.com/pub.10.1038/leu.2012.216

0 references

Update on therapy of chronic lymphocytic leukemia

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.216

21 January 2018

Improving survival in patients with chronic lymphocytic leukemia (1980-2008): the Hospital Clinic of Barcelona experience

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.216

21 January 2018

Eradication of minimal residual disease in B-cell chronic lymphocytic leukemia after alemtuzumab therapy is associated with prolonged survival

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.216

21 January 2018

Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.216

21 January 2018

Comparative analysis of minimal residual disease detection using four-color flow cytometry, consensus IgH-PCR, and quantitative IgH PCR in CLL after allogeneic and autologous stem cell transplantation.

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.216

21 January 2018

Clinical significance of minimal residual disease, as assessed by different techniques, after stem cell transplantation for chronic lymphocytic leukemia.

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.216

21 January 2018

Long-term results of the fludarabine, cyclophosphamide, and rituximab regimen as initial therapy of chronic lymphocytic leukemia

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.216

21 January 2018

Alemtuzumab compared with chlorambucil as first-line therapy for chronic lymphocytic leukemia

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.216

21 January 2018

Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.216

21 January 2018

Assessment of fludarabine plus cyclophosphamide for patients with chronic lymphocytic leukaemia (the LRF CLL4 Trial): a randomised controlled trial

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.216

21 January 2018

Campath-1H and fludarabine in combination are highly active in refractory chronic lymphocytic leukemia

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.216

21 January 2018

Rituximab, fludarabine, cyclophosphamide, and mitoxantrone: a new, highly active chemoimmunotherapy regimen for chronic lymphocytic leukemia.

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.216

21 January 2018

Fludarabine, cyclophosphamide, and mitoxantrone as initial therapy of chronic lymphocytic leukemia: high response rate and disease eradication

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.216

21 January 2018

Diagnostic criteria for monoclonal B-cell lymphocytosis

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.216

21 January 2018

Minimal residual disease detection in mantle cell lymphoma: methods and significance of four-color flow cytometry compared to consensus IGH-polymerase chain reaction at initial staging and for follow-up examinations.

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.216

21 January 2018

Human peripheral blood B-cell compartments: a crossroad in B-cell traffic.

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.216

21 January 2018

Quantitation of minimal disease levels in chronic lymphocytic leukemia using a sensitive flow cytometric assay improves the prediction of outcome and can be used to optimize therapy

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.216

21 January 2018

Flow cytometry APC-tandem dyes are degraded through a cell-dependent mechanism.

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.216

21 January 2018

A randomized phase II trial of fludarabine, cyclophosphamide and mitoxantrone (FCM) with or without rituximab in previously treated chronic lymphocytic leukaemia.

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.216

21 January 2018

High-throughput VDJ sequencing for quantification of minimal residual disease in chronic lymphocytic leukemia and immune reconstitution assessment

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.216

21 January 2018

A probabilistic approach for the evaluation of minimal residual disease by multiparameter flow cytometry in leukemic B-cell chronic lymphoproliferative disorders.

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.216

21 January 2018

Evaluation of Residual Disease in B-Cell Chronic Lymphocytic Leukemia Patients in Clinical and Bone-Marrow Remission Using CD5-CD19 Markers and PCR Study of Gene Rearrangements

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.216

21 January 2018

Minimal residual disease quantification is an independent predictor of progression-free and overall survival in chronic lymphocytic leukemia: a multivariate analysis from the randomized GCLLSG CLL8 trial

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.216

7 January 2021

based on heuristic

inferred from DOI database lookup

International standardized approach for flow cytometric residual disease monitoring in chronic lymphocytic leukaemia.

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.216

7 January 2021

based on heuristic

inferred from DOI database lookup

Standardized MRD flow and ASO IGH RQ-PCR for MRD quantification in CLL patients after rituximab-containing immunochemotherapy: a comparative analysis

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.216

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1038/LEU.2012.216

1 reference

Europe PubMed Central

PubMed publication ID

3 December 2017

Dimensions Publication ID

0 references

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

3 December 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q44539030&oldid=1766263869"